Absence of venous valves in mice lacking Connexin37

Developmental Biology

Volumn 373, Issue 2, 2013, Pages 338-348

  Munger, Stephanie J ^a   Kanady, John D ^a   Simon, Alexander M ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic venous disease; Connexin; Cx37; Gap junction; Venous valve; Wound healing

Indexed keywords

CONNEXIN 37; CONNEXIN 43; CONNEXIN 47;

AGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL COMMUNICATION; CONTROLLED STUDY; ENDOTHELIUM; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PERIPHERAL VEIN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; VEIN BLOOD FLOW; VEIN VALVE; VENOUS VALVE ABSENCE;

MUS;

EID: 84871682633     PISSN: 00121606     EISSN: 1095564X     Source Type: Journal    
DOI: 10.1016/j.ydbio.2012.10.032     Document Type: Article

References (59)

1. Alonso F., Krattinger N., Mazzolai L., Simon A., Waeber G., Meda P., Haefliger J.A. An angiotensin II- and NF-kappaB-dependent mechanism increases connexin 43 in murine arteries targeted by renin-dependent hypertension. Cardiovasc. Res. 2010, 87:166-176.
2. Bazigou E., Lyons O.T., Smith A., Venn G.E., Cope C., Brown N.A., Makinen T. Genes regulating lymphangiogenesis control venous valve formation and maintenance in mice. J. Clin. Invest. 2011, 121:2984-2992.
3. Bazigou E., Xie S., Chen C., Weston A., Miura N., Sorokin L., Adams R., Muro A.F., Sheppard D., Makinen T. Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis. Dev. Cell 2009, 17:175-186.
4. Becker D.L., Thrasivoulou C., Phillips A.R. Connexins in wound healing; perspectives in diabetic patients. Biochim. Biophys. Acta 2011, 1818:2068-2075.
5. Bruzzone R., Haefliger J.A., Gimlich R.L., Paul D.L. Connexin40, a component of gap junctions in vascular endothelium, is restricted in its ability to interact with other connexins. Mol. Biol. Cell 1993, 4:7-20.
6. Caggiati C., Bonati M.R., Pieri P., Riva R. 1603-2003: Four Centuries of Valves. Eur. J. Vasc. Endovasc. Surg. 2004, 28:439-441.
7. Chang C.J., Wu L.S., Hsu L.A., Chang G.J., Chen C.F., Yeh H.I., Ko Y.S. Differential endothelial gap junction expression in venous vessels exposed to different hemodynamics. J. Histochem. Cytochem. 2010, 58:1083-1092.
8. Chew S.S., Johnson C.S., Green C.R., Danesh-Meyer H.V. Role of connexin43 in central nervous system injury. Exp. Neurol. 2010, 225:250-261.
9. Coutinho P., Qiu C., Frank S., Tamber K., Becker D. Dynamic changes in connexin expression correlate with key events in the wound healing process. Cell. Biol. Int. 2003, 27:525-541.
10. Cronin M., Anderson P.N., Cook J.E., Green C.R., Becker D.L. Blocking connexin43 expression reduces inflammation and improves functional recovery after spinal cord injury. Mol. Cell Neurosci. 2008, 39:152-160.
11. Davy A., Bush J.O., Soriano P. Inhibition of gap junction communication at ectopic Eph/ephrin boundaries underlies craniofrontonasal syndrome. PLoS Biol. 2006, 4:e315.
12. Dbouk H.A., Mroue R.M., El-Sabban M.E., Talhouk R.S. Connexins: a myriad of functions extending beyond assembly of gap junction channels. Cell Commun. Signal 2009, 7:4.
13. Ek-Vitorin, J.F., Burt, J.M. Structural basis for the selective permeability of channels made of communicating junction proteins.Biochim. Biophys. Acta, , in press. http://dx.doi.org/10.1016/j.bbamem.2012.02.003.
14. Fang J., Dagenais S.L., Erickson R.P., Arlt M.F., Glynn M.W., Gorski J.L., Seaver L.H., Glover T.W. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am. J. Hum. Genet. 2000, 67:1382-1388.
15. Fang J.S., Angelov S.N., Simon A.M., Burt J.M. Cx37 deletion enhances vascular growth and facilitates ischemic limb recovery. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H1872-H1881.
16. Ferrell R.E., Baty C.J., Kimak M.A., Karlsson J.M., Lawrence E.C., Franke-Snyder M., Meriney S.D., Feingold E., Finegold D.N. GJC2 Missense mutations cause human lymphedema. Am. J. Hum. Genet. 2010, 86:943-948.
17. Francis R., Xu X., Park H., Wei C.J., Chang S., Chatterjee B., Lo C. Connexin43 modulates cell polarity and directional cell migration by regulating microtubule dynamics. PLoS One 2011, 6:e26379.
18. Gabriels J.E., Paul D.L. Connexin43 is highly localized to sites of disturbed flow in rat aortic endothelium but connexin37 and connexin40 are more uniformly distributed. Circ. Res. 1998, 83:636-643.
19. Ghatnekar G.S., O'Quinn M.P., Jourdan L.J., Gurjarpadhye A.A., Draughn R.L., Gourdie R.G. Connexin43 carboxyl-terminal peptides reduce scar progenitor and promote regenerative healing following skin wounding. Regen. Med. 2009, 4:205-223.
20. Goodenough D.A., Paul D.L. Gap junctions. Cold Spring Harb. Perspect Biol. 2009, 1:a002576.
21. Inai T., Shibata Y. Heterogeneous expression of endothelial connexin (Cx) 37, Cx40, and Cx43 in rat large veins. Anat. Sci. Int. 2009, 84:237-245.
22. Jiang J.X., Gu S. Gap junction- and hemichannel-independent actions of connexins. Biochim. Biophys. Acta 2005, 1711:208-214.
23. Kameritsch P., Pogoda K., Pohl U. Channel-independent influence of connexin 43 on cell migration. Biochim. Biophys. Acta 2011, 1818:1993-2001.
24. Kampmeier O.F., La Fleur Birch C. The origin and development of the venous valves, with particular reference to the saphenous district. Am. J. Anat. 1927, 38:451-499.
25. Kanady J.D., Dellinger M.T., Munger S.J., Witte M.H., Simon A.M. Connexin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothorax. Dev. Biol. 2011, 354:253-266.
26. Kanady J.D., Simon A.M. Lymphatic communication: connexin junction, what's your function?. Lymphology 2011, 44:95-102.
27. Kumai M., Nishii K., Nakamura K., Takeda N., Suzuki M., Shibata Y. Loss of connexin45 causes a cushion defect in early cardiogenesis. Development 2000, 127:3501-3512.
28. Kurosaka M., Suzuki T., Hosono K., Kamata Y., Fukamizu A., Kitasato H., Fujita Y., Majima M. Reduced angiogenesis and delay in wound healing in angiotensin II type 1a receptor-deficient mice. Biomed. Pharmacother 2009, 63:627-634.
29. Laird D.W. Life cycle of connexins in health and disease. Biochem. J. 2006, 394:527-543.
30. Laird D.W. The gap junction proteome and its relationship to disease. Trends Cell Biol. 2010, 20:92-101.
31. Lim C.S., Davies A.H. Pathogenesis of primary varicose veins. Br. J. Surg. 2009, 96:1231-1242.
32. Lurie F., Kistner R.L., Eklof B., Kessler D. Mechanism of venous valve closure and role of the valve in circulation: a new concept. J. Vasc. Surg. 2003, 38:955-961.
33. Matsuuchi, L., Naus, C.C., Gap junction proteins on the move: connexins, the cytoskelet on and migration. Biochim. Biophys. Acta, , in press. http://dx.doi.org/10.1016/j.bbamem.2012.05.014.
34. Márquez-Rosado L., Singh D., Rincón-Arano H., Solan J.L., Lampe P.D. CASK (LIN2) interacts with Cx43 in wounded skin and their coexpression affects cell migration. J. Cell Sci. 2012, 125:695-702.
35. Mäkinen T., Adams R.H., Bailey J., Lu Q., Ziemiecki A., Alitalo K., Klein R., Wilkinson G.A. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes. Dev. 2005, 19:397-410.
36. Meissner M.H., Gloviczki P., Bergan J., Kistner R.L., Morrison N., Pannier F., Pappas P.J., Rabe E., Raju S., Villavicencio J.L. Primary chronic venous disorders. J. Vasc. Surg. 2007, 46:54S-67S. Suppl S.
37. Mellor, R.H., Brice, G., Stanton, A.W., French, J., Smith, A., Jeffery, S., Levick, J.R., Burnand, K.G., Mortimer, P.S., 2007. Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb. Circulation. 115, 1912-1920.
38. Mendoza-Naranjo A., Cormie P., Serrano A.E., Hu R., O'Neill S., Wang C.M., Thrasivoulou C., Power K.T., White A., Serena T., Phillips A.R., Becker D.L. Targeting cx43 and N-cadherin, which are abnormally upregulated in venous leg ulcers, influences migration, adhesion and activation of rho GTPases. PLoS One 2012, 7:e37374.
39. Menichella D.M., Goodenough D.A., Sirkowski E., Scherer S.S., Paul D.L. Connexins are critical for normal myelination in the CNS. J. Neurosci. 2003, 23:5963-5973.
40. Ng M.Y., Andrew T., Spector T.D., Jeffery S. Linkage to the FOXC2 region of chromosome 16 for varicose veins in otherwise healthy, unselected sibling pairs. J. Med. Genet. 2005, 42:235-239.
41. Norrmén C., Tammela T., Petrova T.V., Alitalo K. Biological basis of therapeutic lymphangiogenesis. Circulation 2011, 123:1335-1351.
42. Odermatt B., Wellershaus K., Wallraff A., Seifert G., Degen J., Euwens C., Fuss B., Büssow H., Schilling K., Steinhäuser C., Willecke K. Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS. J. Neurosci. 2003, 23:4549-4559.
43. Okamoto T., Akiyama M., Takeda M., Gabazza E.C., Hayashi T., Suzuki K. Connexin32 is expressed in vascular endothelial cells and participates in gap-junction intercellular communication. Biochem. Biophys. Res. Commun. 2009, 382:264-268.
44. Oklu R., Habito R., Mayr M., Deipolyi A.R., Albadawi H., Hesketh R., Walker T.G., Linskey K.R., Long C.A., Wicky S., Stoughton J., Watkins M.T. Pathogenesis of varicose veins. J. Vasc. Interv. Radiol. 2012, 23:33-39.
45. Ostergaard P., Simpson M.A., Brice G., Mansour S., Connell F.C., Onoufriadis A., Child A.H., Hwang J., Kalidas K., Mortimer P.S., Trembath R., Jeffery S. Rapid identification of mutations in GJC2 in primary lymphoedema using whole exome sequencing combined with linkage analysis with delineation of the phenotype. J. Med. Genet. 2011, 48:251-255.
46. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 2007, 8:49-62.
47. Raffetto J.D., Khalil R.A. Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology 2008, 23:85-98.
48. Reaume A.G., de Sousa P.A., Kulkarni S., Langille B.L., Zhu D., Davies T.C., Juneja S.C., Kidder G.M., Rossant J. Cardiac malformation in neonatal mice lacking connexin43. Science 1995, 267:1831-1834.
49. Rodgers K., Abiko M., Girgis W., Amand K., Campeau J., diZerega G. Acceleration of dermal tissue repair by angiotensin II. Wound Repair Regen. 1997, 5:175-183.
50. Sabine A., Agalarov Y., Maby-El Hajjami H., Jaquet M., Hägerling R., Pollmann C., Bebber D., Pfenniger A., Miura N., Dormond O., Calmes J.M., Adams R.H., Mäkinen T., Kiefer F., Kwak B.R., Petrova T.V. Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation. Dev. Cell 2012, 22:430-445.
51. Shiojiri N., Niwa T., Sugiyama Y., Koike T. Preferential expression of connexin37 and connexin40 in the endothelium of the portal veins during mouse liver development. Cell Tissue Res. 2006, 324:547-552.
52. Simon A.M., Chen H., Jackson C.L. Cx37 and Cx43 localize to zona pellucida in mouse ovarian follicles. Cell Commun. Adhes. 2006, 13:61-77.
53. Simon A.M., Goodenough D.A., Li E., Paul D.L. Female infertility in mice lacking connexin 37. Nature 1997, 385:525-529.
54. Simon A.M., McWhorter A.R. Vascular abnormalities in mice lacking the endothelial gap junction proteins connexin37 and connexin40. Dev. Biol. 2002, 251:206-220.
55. Solan J.L., Lampe P.D. Connexin43 phosphorylation: structural changes and biological effects. Biochem. J. 2009, 419:261-272.
56. Srinivasan R.S., Oliver G. Prox1 dosage controls the number of lymphatic endothelial cell progenitors and the formation of the lymphovenous valves. Genes. Dev. 2011, 25:2187-2197.
57. Stout C., Goodenough D.A., Paul D.L. Connexins: functions without junctions. Curr. Opin. Cell Biol. 2004, 16:507-512.
58. Takeda H., Katagata Y., Hozumi Y., Kondo S. Effects of angiotensin II receptor signaling during skin wound healing. Am. J. Pathol. 2004, 165:1653-1662.
59. Yahata Y., Shirakata Y., Tokumaru S., Yang L., Dai X., Tohyama M., Tsuda T., Sayama K., Iwai M., Horiuchi M., Hashimoto K. A novel function of angiotensin II in skin wound healing. Induction of fibroblast and keratinocyte migration by angiotensin II via heparin-binding epidermal growth factor (EGF)-like growth factor-mediated EGF receptor transactivation. J. Biol. Chem. 2006, 281:13209-13216.